Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H32O2 |
| Molecular Weight | 304.4669 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C
InChI
InChIKey=UXYRZJKIQKRJCF-TZPFWLJSSA-N
InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1
| Molecular Formula | C20H32O2 |
| Molecular Weight | 304.4669 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Proviron_dr_1358760414396.pdfCurator's Comment: description was created based on several sources, including, https://www.steroidal.com/steroid-profiles/proviron-mesterolone/
Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Proviron_dr_1358760414396.pdf
Curator's Comment: description was created based on several sources, including, https://www.steroidal.com/steroid-profiles/proviron-mesterolone/
Mesterolone is an androgen receptor agonist which was developed for hormone replacement therapy in males suffering from androgen deficiency and related disorders. Mesterolone is known under the name Proviron. The drug is also used by bodybuilders and athletes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10935543 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
| Palliative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
| Curative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
| Primary | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
150 mg 1 times / day steady-state, oral Studied dose Dose: 150 mg, 1 times / day Route: oral Route: steady-state Dose: 150 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
450 mg 1 times / day steady-state, oral Studied dose Dose: 450 mg, 1 times / day Route: oral Route: steady-state Dose: 450 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Successful treatment of methimazole-induced severe aplastic anaemia in a diabetic patient with other co-morbidities. | 2010-12-20 |
|
| Effect of high intensity aerobic exercise and mesterolone on remodeling of Achilles tendon of C57BL/6 transgenic mice. | 2010-02 |
|
| Morphological changes in murine skeletal muscle in response to exercise and mesterolone. | 2010 |
|
| Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. | 2009-07-07 |
|
| Hepatocyte nuclear phenotype: the cross-talk between anabolic androgenic steroids and exercise in transgenic mice. | 2008-11 |
|
| Adverse effect of the anabolic-androgenic steroid mesterolone on cardiac remodelling and lipoprotein profile is attenuated by aerobicz exercise training. | 2008-10 |
|
| Microbial oxidation of anabolic steroids. | 2008 |
|
| Nonsurgical treatment of male infertility: specific and empiric therapy. | 2007-09 |
|
| Metabolic studies of mesterolone in horses. | 2007-07-16 |
|
| Molecular cloning and characterization of a nuclear androgen receptor activated by 11-ketotestosterone. | 2005-08-17 |
|
| Microbial transformation of mesterolone. | 2005-03 |
|
| Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency. | 2005 |
|
| The role of the biochemistry department in the diagnosis of pituitary apoplexy. | 2004-03 |
|
| Human chorionic gonadotropin free beta-subunit in the human seminal plasma: a new marker for spermatogenesis? | 2003-02-10 |
|
| Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. | 2003 |
|
| Oligospermia due to partial maturation arrest responds to low dose estrogen-testosterone combination therapy resulting in live-birth: a case report. | 2002-12 |
|
| Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto-5alpha-steroid-17-O-beta glucuronides and 5alpha-steroid-3alpha,17beta-diol 3- and 17-glucuronides. | 2001-09 |
Patents
Sample Use Guides
The tablets should be swallowed whole with some liquid. The recommended doses are: 1 tablet (25 mg) 3 times/day (reduced efficiency and potency disturbances), 1 tablet 2-3 times/day (Infertility), 1-2 tablets 3 times/day (for development of secondary male sex characteristics in hypogonadism).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10935543
Mesterolone showed activation effect on mutant androgen receptor (expressed in HeLa and COS-7 cells) at doses 0.1–300 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:57:06 GMT 2025
by
admin
on
Wed Apr 02 06:57:06 GMT 2025
|
| Record UNII |
0SRQ75X9I9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
4000
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
||
|
WIKIPEDIA |
Designer-drugs-Mesterolone
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
||
|
WHO-VATC |
QG03BB01
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
||
|
WHO-ATC |
G03BB01
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
75054
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
3342
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
C87227
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
215-836-3
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
100000091044
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
6781
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | RxNorm | ||
|
1424-00-6
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
DTXSID90878533
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
15020
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
0SRQ75X9I9
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
D008655
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
SUB08790MIG
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
MESTEROLONE
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
1965
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
CHEMBL258918
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
DB13587
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
m7256
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |